Moreno, D. F.Fernández de Larrea Rodríguez, Carlos José2024-02-062024-06-272023-08-010889-8588https://hdl.handle.net/2445/207222With the increasing availability of sequencing techniques and new polymerase chain reaction-based methods, data regarding the genomic profile of Waldenström macroglobulinemia (WM) are being continuously analyzed and reproduced. MYD88 and CXCR4 mutations are highly prevalent in all the stages of WM, including the early IgM monoclonal gammopathy of undetermined significance or a more advanced stage, such as smoldering WM. Thus, there is a need to define genotypes before starting either standard treatment regimens or clinical trials. Here, we review the genomic profile of WM and its clinical implications while focusing on recent advances.Copyright © 2023 Elsevier Inc. All rights reserved.15 p.application/pdfengcc by-nc-nd (c) Elsevier, 2024http://creativecommons.org/licenses/by-nc-nd/3.0/es/LimfomesMutació (Biologia)LymphomasMutation (Biology)info:eu-repo/semantics/article2024-02-06info:eu-repo/semantics/openAccess935488637211494